Soleimani Fatemeh, Fahimi Fanak, Adimi Naghan Parisa, Nadji Seyed Alireza, Morowati Saeid, Naderi Nima, Masjedi Mohammad Reza
Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Allergy Asthma Immunol. 2013 Aug 28;12(4):383-90.
The results of many studies suggested possible relationship between polymorphism at codons 16 and 27 and development of tolerance to beta-2 adrenoceptor agonist responses as well as disease severity in asthmatic patients. This study was designed to evaluate the effect of polymorphism of beta2 adrenoceptors on response to salmeterol and fluticasone (as inhaled Seretide).Sixty-four patients with either mild or moderate-severe asthma were evaluated in this study. A four-week therapy with Seretide was conducted in moderate-severe asthmatics. The respiratory parameters and asthma score (based on GINA guidelines) were measured before and after run in period. Blood samples were genotyped at codons 16 and 27.No significant difference was observed in genotypes neither at codon 16 nor at codon 27 between mild and moderate-severe asthma groups. However, Patients in Arg/Arg (n = 8) category showed significant improvement in asthma control parameters and lung function compared with Arg/Gly genotype (n =20).These results suggest that genotyping may be useful in some asthmatic patients in order to better tailor asthma treatment plan.
许多研究结果表明，密码子16和27处的多态性与哮喘患者对β-2肾上腺素能受体激动剂反应的耐受性发展以及疾病严重程度之间可能存在关联。本研究旨在评估β2肾上腺素能受体多态性对沙美特罗和氟替卡松（吸入用舒利迭）反应的影响。本研究对64例轻度或中度重度哮喘患者进行了评估。对中度重度哮喘患者进行了为期四周的舒利迭治疗。在导入期前后测量呼吸参数和哮喘评分（基于GINA指南）。对血样进行密码子16和27的基因分型。轻度和中度重度哮喘组在密码子16和密码子27处的基因型均未观察到显著差异。然而，与Arg/Gly基因型（n = 20）相比，Arg/Arg类别（n = 8）的患者在哮喘控制参数和肺功能方面有显著改善。这些结果表明，基因分型可能对某些哮喘患者有用，以便更好地制定哮喘治疗方案。
